BCL2L1 and cancer: Our findings also confirmed that sensitivity to anticancer drugs increased in the absence of LKB1 via downregulation of Bcl-xL, indicating that at least the activity of LKB1 must be suppressed to increase cancer cell death (Fig. 6E).